» Articles » PMID: 31376036

Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2019 Aug 4
PMID 31376036
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increasing evidence suggests that cancer progression is strongly influenced by the host immune response, which is represented by immune cell infiltrates. The T-lymphocyte-based Immunoscore is reported to be a reliable prognostic factor in colon cancer, but its significance in urothelial carcinoma of the bladder (UCB) is at an early stage of exploration. This study aimed to determine whether the tumor immune infiltrate, as evaluated by the Immunoscore, could act as a useful prognostic marker for UCB patients who have undergone radical cystectomy (RC).

Methods: In this study, immunohistochemistry was used to examine the Immunoscore of 221 UCB patients who underwent RC. The Immunoscore of the patients was determined by the densities of CD3+ and CD8+ T cells at the tumor center and the invasive margin.

Results: A highly significant association between a low Immunoscore and a shortened patient survival (P < 0.001, log-rank test) was demonstrated. In different subsets of UCB patients, a low Immunoscore also was a prognostic indicator of pT ≤ 2, pN(-)-status tumors, negative vascular invasion, or both (P < 0.05). Importantly, the Immunoscore together with the patient's pT status provided significant independent prognostic parameters in the multivariate analysis (P < 0.05). Furthermore, a significant correlation (P = 0.003) of a low Immunoscore with an increased UCB labeling index of Ki-67 (a cell proliferation marker) was observed in this UCB cohort.

Conclusions: The findings suggest that the Immunoscore, as examined by immunohistochemistry, might serve as a novel prognostic marker for UCB patients who have undergone RC.

Citing Articles

CD45RO-Positive Memory T-Cell Density in the Tumoral Core and Invasive Margin Predict Long-Term Survival in Esophageal Squamous Cell Carcinoma.

Noma T, Makino T, Ohshima K, Yamashita K, Saito T, Tanaka K Ann Surg Oncol. 2024; 32(3):1953-1962.

PMID: 39638991 PMC: 11811247. DOI: 10.1245/s10434-024-16530-z.


Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.

Chen D, Cao H, Zheng X, Wang H, Han Z, Wang W BMC Cancer. 2024; 24(1):1024.

PMID: 39160525 PMC: 11331755. DOI: 10.1186/s12885-024-12790-w.


Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.

Ben Rejeb S, Elfekih S, Kouki N, Boulma R, Khouni H J Egypt Natl Canc Inst. 2024; 36(1):9.

PMID: 38523233 DOI: 10.1186/s43046-024-00212-8.


The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors.

Eljilany I, Saghand P, Chen J, Ratan A, McCarter M, Carpten J Cancers (Basel). 2023; 15(20).

PMID: 37894280 PMC: 10605389. DOI: 10.3390/cancers15204913.


Characterization of Epithelial-Mesenchymal Transition Identifies a Gene Signature for Predicting Clinical Outcomes and Therapeutic Responses in Bladder Cancer.

Wang Y, Zhang H, Hu X Dis Markers. 2022; 2022:9593039.

PMID: 36457546 PMC: 9708359. DOI: 10.1155/2022/9593039.